By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

Thousands of men with advanced prostate cancer could soon live longer thanks to a treatment which cuts the risk of the ...

The Expander-2 trial randomly assigned men with BPH symptoms at 23 sites in the US and Canada to receive a temporary nitinol urethral implant, Urocross Expander, or a sham procedure.

Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...

The Keller, Roanoke and north Fort Worth areas have seen several updates to the local hospital systems in or near the cities, including new programs and build-outs.

Advances in radiotherapy are rapidly transforming how prostate cancer is treated, offering patients more precise, less invasive options that can fit more easily around everyday life ...

With advanced robotic systems and 5G connectivity, top-tier surgeons can now operate on patients thousands of kilometers away ...

A new podcast fronted by writer, comedian and broadcaster Jon Holmes is aiming to help men better understand their prostate cancer treatment options ...

Only men with a specific gene variant and a family history of certain cancers should be screened, experts have said.